PDCD1 and neoplasm: Durvalumab (IMFINZI®), an immune checkpoint inhibitor, is a selective, high-affinity human immunoglobulin G1 kappa monoclonal antibody that blocks programmed death-ligand 1 (PD-L1) binding to programmed cell death protein 1 (PD-1) and CD80, enabling T cells to recognize and kill tumor cells.